



News Release

HYDERABAD, INDIA (5 June' 2020) -- SUVEN Life Sciences Limited ("Suven", "Company") today announced audited financial results for the quarter and year ended 31 Mar 2020. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 5 June' 2020 at Hyderabad.

CONDENCED STATEMENT OF OPERATIONS

All figures in INR Lakhs, except EPS

	Stand Alone - 3 Months ended			FY-Stand Alone ^(b)		FY-Consolidated ^{(b)(d)}	
	Mar-20	Dec-19	Mar-19	Mar-20	Mar-19	Mar-20	Mar-19
Revenue	1,165.71	862.79	817.02	2,845.10	31,291.47	2,845.10	31,291.47
R&D and Operational expenses	1,073.74	1,213.41	2,052.70	4,967.81	23,696.86	13,013.17	30,005.58
Depreciation and Amortization	105.24	85.50	80.18	416.87	1,078.97	416.87	1,078.97
Finance cost	23.21	9.81	29.07	54.03	190.26	55.14	191.33
Total expenses	1,202.19	1,308.72	2,161.95	5,438.71	24,966.09	13,485.18	31,275.88
Tax	219.87	4.22	(407.19)	(1,218.29)	2,406.01	(1,218.29)	2,406.01
Profit/(Loss) After Tax for the period/year	(256.35)	(450.15)	(937.74)	(1,375.32)	3,919.37	(9,421.79)	(2,390.42)
Other comprehensive income	(18.79)	(9.37)	6.89	(29.54)	(13.77)	(29.54)	(13.77)
Total comprehensive income	(275.14)	(459.52)	(930.85)	(1,404.86)	3,905.60	(9,451.33)	(2,404.19)
Paid up equity capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
Earnings per share of Rs.1 each (EPS)	(0.20)	(0.35)	(0.74)	(1.08)	3.08	(7.40)	(1.88)

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The Company has become Demerged entity effective 1 Oct 2018 and hence the annual figures of previous year are not comparable

(c) Post demerger, approved by Honorable National Company Law Tribunal (NCLT) on 6 Jan 2020, the CRAMS operations of the Company were demerged into Suven Pharmaceuticals Limited (the Resultant entity) and the Company continue to focus on NCE based Research and Development.

(d) Consolidated statement includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(e) Suven presented exploratory sub-group analyses data from completed Masupirdine (SUVN-502) Phase 2A proof of concept Study in Patients with Moderate Alzheimer's Disease (AD) at the **Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD™) focus meeting 2020** in April 2020. This meeting, originally scheduled to take place in Vienna, Austria, was converted to a virtual meeting due to the COVID-19 pandemic.

(f) Based on the encouraging results in sub-group analysis of SUVN-502 for some of the secondary endpoints, Suven is in consultation with KOL to finalize the indication for Phase 2 POC study. The same will be initiated before end of the year.

(g) Suven's ongoing phase 2 study in USA on SUVN-G3031, targeted against Narcolepsy (excessive day time sleep disorder), will be delayed by few months due to the impact of COVID-19 pandemic in USA.

(h) Since last reporting period, the Company has been granted 20 patents for its innovative drug discovery covering ARIPO, Brazil, Eurasia, Israel, Japan, Mexico, New Zealand, South Africa and South Korea.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive;

CIN: L24110TG1989PLC009713

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com